• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Better Therapeutics reaches key milestones for prescription digital therapeutics

April 6, 2022 By Sean Whooley

Better TherapeuticsBetter Therapeutics (Nasdaq:BTTX) announced today that it hit multiple key research milestones as it validates its digital therapeutics.

San Francisco-based Better Therapeutics develops prescription digital therapeutics designed to deliver a novel form of cognitive-behavioral therapy for treating cardiometabolic diseases, potentially improving key measures related to type 2 diabetes, hypertension and more.

Better Therapeutics’ platform aims to address the cognitive patterns that drive eating habits and other behavioral factors associated with such diseases.

The company reported the outcomes of three studies, including the first study of nutritional cognitive behavioral therapy (nCBT) as a potential treatment for nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH), according to a news release.

In collaboration with Arizona Liver Health, the company has commenced the LivVita study for evaluating the feasibility of nCBT in reducing liver fat and improving liver disease biomarkers in NAFLD and NASH. The study recently enrolled its first patients.

Additionally, the company expanded its real-world evidence study of BT-001 to include Mass General Brigham. That study has begun enrolling patients with type 2 diabetes as it aims to demonstrate statistically significant and clinically meaningful reductions in the A1c measure of blood sugar. Recent primary endpoint data demonstrated such reduction, the company said.

Finally, the company announced that the Durham Veterans Administration Medical Center joined the real-world evidence study for BT-001 held in collaboration with the Colorado Prevention Center.

“Demonstrating the potential to improve and maintain glycemic control and reduce ongoing healthcare costs and medications within the veteran community is of critical importance,” Better Therapeutics CMO Dr. Mark Berman said in the release. “Veterans suffer disproportionately from type 2 diabetes, which is the largest driver of costs within the VA.”

Filed Under: Business/Financial News, Clinical Trials, Diabetes, Drug-Device Combinations, Featured, Technology Tagged With: Better Therapeutics

IN CASE YOU MISSED IT

  • Insulet hires new chief HR officer from J&J
  • Breakthrough T1D, Mattel debut Barbie doll with type 1 diabetes
  • Medtronic Diabetes names CFO with consumer experience ahead of separation
  • Diabeloop launches insulin delivery algorithm in Germany
  • GlucoModicum has positive data for needle-free CGM

About Sean Whooley

Sean Whooley is an associate editor who mainly produces work for MassDevice, Medical Design & Outsourcing and Drug Delivery Business News. He received a bachelor's degree in multiplatform journalism from the University of Maryland, College Park. You can connect with him on LinkedIn or email him at swhooley@wtwhmedia.com.

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS